Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
Date:11/18/2011

CAMBRIDGE, Mass., Nov. 18, 2011 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer (NSCLC). 

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO )

The Phase 2 study is designed to estimate Progression Free Survival (PFS) when combining MM-121 and erlotinib in three distinct metastatic NSCLC patient populations:

  • Group A includes patients whose tumors do not have an EGFR activating mutation.  The patient's cancer must have recurred or progressed following at least one chemotherapy-containing regimen and who have not received prior EGFR targeted therapy. They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group B includes patients whose tumors have an EGFR activating mutation.  The patients must have not received prior EGFR targeted therapy.  They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group C includes patients whose tumors had responded to EGFR targeted therapy and have subsequently acquired resistance. They will receive MM-121 in combination with erlotinib.

The study is being conducted at multiple sites in North America, Europe and Asia. The trial is designed to enroll approximately 229 patients across all three arms.  The first patient was enrolled at the Loma Linda University Cancer Center.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack 

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
4. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
5. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
6. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
7. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
10. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
11. Idenix Pharmaceuticals Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Regenicin, ... a biotechnology company specializing in the development and commercialization ... damaged tissues and organs, recently reported the Company,s operating ... for 2017. As the Company described in ... been a year of substantial accomplishments. The Company,s contract ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017 /PRNewswire/ ... líderes lanzaron Access Accelerated, una iniciativa global para avanzar ... (NCD) y atención en países de renta baja y ... han alcanzado un punto de crisis, particularmente en países ... el 80 por ciento de las muertes relacionadas con ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... From a health perspective, 2017 will clearly be ... health to chronic disease, mental health and general physical well-being. The New York Times ... to consider. , For one Charlottesville restaurant, good gut health is clearly on the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... leading journal and most-read publication among specialty pharmacists and pharmacy professionals, has ... its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of Pharmacy ...
(Date:1/18/2017)... Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... as a fund raiser for Smile Train, an international charity that provides free surgery ... a hobby of mine and in the past I have run to support the ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... The Portee ... to families and business owners in central Maryland and the DC region, is inaugurating ... disease kills 787,000 people nationally every year, making it the #1 killer in America. ...
Breaking Medicine News(10 mins):